SCHEMBL6844726

SCHEMBL6844726

COc1ccc(CNc2ccc(COc3cccc(C(=O)Nc4ccc(C(C)C)c(C)c4)c3)cn2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
MAPT P10636 1/20 0.49
SMPD1 P17405 1/20 0.48
HDAC1 Q13547 1/20 0.47
NR1H4 Q96RI1 1/20 0.46
HSP90AA1 P07900 1/20 0.46
HSP90AB1 P08238 1/20 0.46
NPC1 O15118 6/20 0.45
RAB9A P51151 6/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
TP53 P04637 2/20 0.45
PGR P06401 1/20 0.45
AR P10275 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
KMT2A Q03164 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6844825 0.87 KMT2A (0.54) ALDH1A1MAPTNR1H4NPC1RAB9A
SCHEMBL6841256 0.83 NR1H4 (0.52) MAPTNR1H4NPC1RAB9ASMN1; SMN2
SCHEMBL6846445 0.83 KCNQ3 (0.55) MAPTNR1H4NPC1RAB9ASMN1; SMN2
SCHEMBL6846794 0.80 NR1H4 (0.48) ALDH1A1MAPTNR1H4NPC1RAB9A
SCHEMBL6846628 0.72 NPC1 (0.48) ALDH1A1MAPTNR1H4HSP90AA1HSP90AB1
SCHEMBL6846662 0.72 NPC1 (0.53) MAPTNR1H4NPC1RAB9ASMN1; SMN2
SCHEMBL15819517 0.70 SMPD1 (0.61) ALDH1A1SMPD1NPC1RAB9ASMN1; SMN2
SCHEMBL15838782 0.70 SMPD1 (0.64) ALDH1A1MAPTSMPD1NR1H4NPC1
SCHEMBL6841450 0.69 RAB9A (0.43) ALDH1A1MAPTHSP90AA1HSP90AB1NPC1
SCHEMBL15825021 0.69 SIRT2 (0.68) ALDH1A1MAPTSMPD1NR1H4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BENDER STEVEN LEE (US) 2004-05-13 US disclosed
US-6635641-B2 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis AGOURON PHARMACEUTICALS, INC. 2003-10-21 US disclosed
EP-1252146-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2002-10-30 EP disclosed
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2002-08-01 US disclosed
WO-2001053274-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2001-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA ALDH1A1 3632/4885MAPT 899/4885SMPD1 1129/4885
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA ALDH1A1 3632/4885MAPT 899/4885SMPD1 1129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.